key: cord-0730196-dg3iw1hf
authors: McDougle, Leon
title: Ensuring Safety of Operation Warp Speed Vaccines for COVID-19
date: 2020-12-05
journal: J Natl Med Assoc
DOI: 10.1016/j.jnma.2020.10.003
sha: 6a51fe5b67ef59fde100ffc2dbea54f5f78814d8
doc_id: 730196
cord_uid: dg3iw1hf

nan

https://doi.org/10.1016/j.jnma.2020.10.003 S afety protocols have been established to help ensure desired outcomes for patients undergoing surgical operations. The protocols are especially helpful during high stress environments involving multiple persons with life threatening injuries and illnesses that require emergency surgical intervention. For example, the Joint Commission's "Speak Up" campaign promotes its universal protocol for preventing wrong site, wrong procedure and wrong person operations. The last step of the safety protocol includes performing a time-out, and the procedure is not started until all questions and concerns are resolved. 1 During the COVID-19 pandemic the United States Food and Drug Administration (FDA) approved emergency use authorization (EUA) for hydroxychloroquine and convalescent plasma. 2, 3 In both cases the established safety protocols involving completion of Phase 3 clinical trials for treatment of SARS-CoV-2 were bypassed. There were no apparent clinical trial equivalents to a surgical operation time-out.

Hydroxychloroquine was later found to have "serious cardiac adverse events" when used for treatment of patients with COVID-19 4 and a panel of scientists from the National Institutes of Health released the following statement about use of convalescent plasma on September 1, 2020 5 :

There are insufficient data to recommend either for or against the use of convalescent plasma for the treatment of COVID-19.

Available data suggest that serious adverse reactions following the administration of COVID-19 convalescent plasma are infrequent and consistent with the risks associated with plasma infusions for other indications.

The long-term risks of treatment with COVID-19 convalescent plasma and whether its use attenuates the immune response to SARS-CoV-2, making patients more susceptible to reinfection, have not been evaluated.

Convalescent plasma should not be considered standard of care for the treatment of patients with COVID-19.

Prospective, well-controlled, adequately powered randomized trials are needed to determine whether convalescent plasma is effective and safe for the treatment of COVID-19. Members of the public and health care providers are encouraged to participate in these prospective clinical trials.

The fact that hydroxychloroquine received EUA approval coupled with the August 23rd EUA approval of convalescent plasma treatment preceding convening of the August 24, 2020 Republican National Convention, have raised serious questions about the role of political influence on decisions made by the FDA. 6 These questions of political influence on scientific process have threatened the trust in the FDA that will be required for African American community uptake of any vaccine developed as a result of Operation Warp Speed (OWS).

The protocols for the OWS clinical trials are overseen by the federal government, as opposed to traditional publicprivate partnerships, in which pharmaceutical companies decide on their own protocols. Rather than eliminating steps from traditional development timelines, the steps have been proceeding simultaneously, such as starting manufacturing of the vaccine at industrial scale well before the demonstration of vaccine efficacy and safety as happens normally. 7

Enrollment of representative percentage of African American participants in the clinical trials will also help to ensure efficacy and safety along with providing evidence to build trust in COVID-19 vaccines and therapeutics that are approved by the FDA. I encourage NMA physicians to help recruit volunteers for COVID-19 clinical trials. People 18 years of age and older who are interested in volunteering for COVID-19 clinical trials can visit https:// www.coronaviruspreventionnetwork.org or ClinicalTrials. gov and search identifier NCT04470427 for details.

To help address questions and concerns about efficacy, safety, and allocation of COVID-19 vaccines and therapeutics a resolution was introduced by former NMA President Dr. Rodney Hood and passed by the House of Delegates in August 4, 2020 to establish a COVID-19 taskforce. The taskforce includes NMA physicians who belong to the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), Infectious Disease Society of America, Pediatric Infectious Disease Society, and the CDC Health Equity Workgroup. The NMA COVID-19 taskforce will be positioned to provide timely recommendations to physicians and the community about future emergency use authorizations by the FDA for COVID-19 vaccines and therapeutics currently undergoing evaluation in clinical trials. The taskforce findings will be especially critical if such an authorization occurs immediately before the November 3rd U.S. election.

The Joint Commission. The Universal Protocol

Emergency use authorization for hydroxychloroquine

FDA issues emergency use authorization for convalescent plasma as potential promising COVIDe19 treatment, another achievement in administration's fight against pandemic

Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine

The COVID-19 treatment guidelines panel's statement on the emergency use authorization of convalescent plasma for the treatment of COVID-19

Timeline: tracking trump alongside scientific developments on hydroxychloroquine

com/Health/timeline-tracking-trump-alongside-scientific-devel opments-hydroxychloroquine/story?id¼72170553

Fact sheet: explaining operation warp speed